How is Abrocitinib synthesized according to US Patent 9,035,074?
U.S. Patent 9,035,074 describes a synthetic route for abrocitinib, a Janus kinase 1 (JAK1) inhibitor. Example 2 of the patent details a specific process for preparing abrocitinib.
What are the key steps in the synthesis described in Example 2?
The synthesis outlined in Example 2 involves the reaction of a pyrazolo[1,5-a]pyrimidine intermediate with a substituted pyrrolidine derivative. The process typically includes steps such as amination, coupling, and purification to yield the final abrocitinib compound [1].
What intermediate compounds are used in this synthesis?
Key intermediate compounds in the synthesis according to Example 2 include specific substituted pyrazolo[1,5-a]pyrimidine and pyrrolidine derivatives that are designed to react and form the abrocitinib molecule [1].
When does the patent for abrocitinib expire?
Information on the specific expiration dates for patents related to abrocitinib, including US Patent 9,035,074, can be found by consulting patent databases. DrugPatentWatch.com provides detailed patent information, including expiration timelines, for various pharmaceuticals [2].
Who is developing abrocitinib?
Abrocitinib is developed by Pfizer Inc. [3].
What is abrocitinib used to treat?
Abrocitinib is a JAK1 inhibitor used for the treatment of moderate-to-severe atopic dermatitis [3].
What are the potential side effects of abrocitinib?
Common side effects associated with abrocitinib include nasopharyngitis, acne, and increased levels of liver enzymes [3].
How does abrocitinib work?
Abrocitinib selectively inhibits Janus kinase 1 (JAK1). By blocking JAK1, it helps to reduce inflammation associated with conditions like atopic dermatitis [3].
What is the mechanism of action of JAK inhibitors?
JAK inhibitors, like abrocitinib, interfere with signaling pathways that are involved in immune responses and inflammation. By inhibiting specific Janus kinases, these drugs can dampen the activity of immune cells and reduce the production of inflammatory substances [3].
---
Sources:
[1] US Patent 9,035,074
[2] https://drugpatentwatch.com/
[3] https://www.pfizer.com/science/drug-discovery/patient-focused-development/abrocitinib